The Journal of Immunology · 2016 · 52 citations · 29 references
Life SciencesImmunologyCell SignalingImmunoregulationSignal TransductionAngiogenesisCytokine BiologyDendritic Cell BiologyDendritic Cell RegulationImmune Cell SignalingImmune MaturationDendritic Cell SignalingImmune Cell Cytokine ProductionImmunosuppressive FunctionPeripheral Immune Cell MaturationSoluble MediatorsT Cell Cytokine ProductionVascular Endothelial Growth FactorVascular Endothelial Growth Factor Receptors
To stimulate a productive T cell response, dendritic cells (DC) must undergo maturation characterized by heightened cell surface expression of MHC and costimulatory molecules as well as cytokine production. Conversely, the inhibition of DC maturation is a central mechanism of immune tolerance. The control of the DC maturation process relies on the integration of several cellular stimulatory or inhibitory signals. The soluble factors and their receptors controlling this central aspect of DC biology are incompletely characterized. We show that murine bone marrow-derived DC (BMDC) maturation induced by LPS, as opposed to polyinosinic:polycytidylic acid or cytosine-phosphate-guanine, is robustly inhibited by vascular endothelial growth factor (VEGF), a previously identified immunosuppressive cytokine. Using BMDC from wild type and conditional knockout mice, we show that neuropilin-1 (NRP-1), a known receptor of VEGF, is necessary to suppress LPS-dependent BMDC maturation. The absence of NRP-1 had no ostensible effects on the biology of BMDC in the absence of VEGF. However, NRP-1-deficient BMDC remained completely insensitive to the VEGF-dependent inhibition of BMDC maturation in culture. In the presence of VEGF, NRP-1 directly interacted with the LPS receptor TLR4 and suppressed downstream signaling through ERK and NF-κβ, resulting in a sharp inhibition of MHC class II and costimulatory molecules (CD40, CD86) expression as well as proinflammatory cytokine production. Consequently, we identify NRP-1 as a target to optimize DC maturation within environments that are rich in VEGF, such as tumors.
29
Kensuke Inaba, Muneo Inaba, Nikolaus Romani et al. · The Journal of Experimental Medicine · 1992 · 3.8K citations · Full text
Vascular endothelial growth factor (VEGF) and its receptors
Gera Neufeld, Tzafra Cohen, Stela Gengrinovitch et al. · The FASEB Journal · 1999 · 3.5K citations
Medicine, Cell Biology, Oncology +17
Katsuaki Hoshino, Osamu Takeuchi, Taro Kawai et al. · The Journal of Immunology · 1999 · 3.4K citations · Full text
Life Sciences, Genetics, Immunology +15